Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
4
×
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
cancer
4
×
deals
4
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
astrazeneca
boston top stories
cancer immunotherapy
clinical trials
eli lilly
gilead sciences
merck
novartis
alzheimer's disease
biogen
What
bio
4
×
roundup
drug
acquisitions
ceo
companies
daniel
gilead
nash
news
o’day
sciences
announced
approval
approved
biggest
biogen’s
biopharmaceutical
build
buy
collabs
company’s
convo
covid
deal
debut
digital
disease
dyne’s
earlier
epidemic
failures
fatty
fda
frenzied
gilead’s
growing
help
introduce
ipo
Language
unset
Current search:
cancer
×
bio
×
abbvie
×
deals
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More